← Eichor
Study identifier: NCT06444009 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Condition: Head and Neck Squamous Cell Carcinoma  ·  Sponsor: Lei Liu

PhasePhase 2
Planned participants90
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

A Randomized, Phase II Study of ivonescimab or cadonilimab or penpulimab in Combination With Cisplatin and Nab-paclitaxel in Patients With locally advanced head and neck squamous cell carcinoma (HNSCC) eligible for resection. This proposed study will evaluate the efficacy and safety of preoperative administration of ivonescimab or cadonilimab or penpulimab combined with chemotherapy in HNSCC who are eligible for resection.

This description comes directly from the study's public registry record.

Talk to the study team

Lei Liu, M.D.  ·  Liu  ·  liuleihx@gmail.com

Yuanyuan Zeng, M.D.  ·  +86-028-85422114  ·  zengyuanyuanpower@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

West China HospitalChengdu, Sichuan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06444009